Goldman Sachs Raises Sarepta Therapeutics (SRPT) Price Target to $127.00

Sarepta Therapeutics (NASDAQ:SRPT) had its price target lifted by equities research analysts at Goldman Sachs to $127.00 in a research report issued on Friday. The brokerage presently has a “buy” rating on the biotechnology company’s stock. Goldman Sachs’ target price points to a potential upside of 38.27% from the company’s previous close.

Several other equities analysts have also weighed in on the stock. Leerink Swann increased their price objective on shares of Sarepta Therapeutics from $88.00 to $121.00 and gave the company an “outperform” rating in a report on Tuesday. Barclays upgraded shares of Sarepta Therapeutics from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $55.00 to $107.00 in a report on Friday, May 11th. Needham & Company LLC increased their price objective on shares of Sarepta Therapeutics from $75.00 to $109.00 and gave the company a “buy” rating in a report on Monday, May 7th. Morgan Stanley increased their price objective on shares of Sarepta Therapeutics from $87.00 to $91.00 and gave the company an “equal weight” rating in a report on Friday, May 4th. Finally, Credit Suisse Group set a $92.00 target price on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Friday, May 4th. Five research analysts have rated the stock with a hold rating, seventeen have given a buy rating and two have issued a strong buy rating to the stock. Sarepta Therapeutics currently has an average rating of “Buy” and a consensus target price of $89.55.

Shares of NASDAQ SRPT opened at $91.85 on Friday. Sarepta Therapeutics has a fifty-two week low of $92.00 and a fifty-two week high of $93.41. The company has a market capitalization of $6.16 billion, a P/E ratio of -56.01 and a beta of 1.34. The company has a current ratio of 13.37, a quick ratio of 12.28 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings data on Thursday, May 3rd. The biotechnology company reported ($0.55) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.32) by ($0.23). Sarepta Therapeutics had a negative net margin of 83.88% and a negative return on equity of 24.68%. The business had revenue of $64.60 million during the quarter, compared to analyst estimates of $65.31 million. During the same quarter in the prior year, the company earned ($0.57) earnings per share. The company’s quarterly revenue was up 295.3% on a year-over-year basis. research analysts predict that Sarepta Therapeutics will post -1.79 EPS for the current fiscal year.

Several hedge funds have recently modified their holdings of SRPT. Carillon Tower Advisers Inc. bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $38,720,000. Gilder Gagnon Howe & Co. LLC increased its position in shares of Sarepta Therapeutics by 63.4% during the fourth quarter. Gilder Gagnon Howe & Co. LLC now owns 872,824 shares of the biotechnology company’s stock worth $48,564,000 after acquiring an additional 338,737 shares in the last quarter. Element Capital Management LLC bought a new stake in shares of Sarepta Therapeutics during the fourth quarter worth $17,706,000. Frontier Capital Management Co. LLC bought a new stake in shares of Sarepta Therapeutics during the first quarter worth $16,940,000. Finally, JPMorgan Chase & Co. increased its position in shares of Sarepta Therapeutics by 36.3% during the first quarter. JPMorgan Chase & Co. now owns 709,070 shares of the biotechnology company’s stock worth $52,535,000 after acquiring an additional 188,841 shares in the last quarter. 85.21% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare neuromuscular diseases. The company offers EXONDYS 51, a disease-modifying therapy for the treatment of duchenne muscular dystrophy (DMD), which is a rare genetic muscle-wasting disease caused by the absence of dystrophin.

Analyst Recommendations for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Albireo  Issues Quarterly  Earnings Results
Albireo Issues Quarterly Earnings Results
Goldman Sachs Raises Sarepta Therapeutics  Price Target to $127.00
Goldman Sachs Raises Sarepta Therapeutics Price Target to $127.00
Brokers Set Expectations for Eli Lilly and Company’s FY2022 Earnings
Brokers Set Expectations for Eli Lilly and Company’s FY2022 Earnings
InflaRx  Posts Quarterly  Earnings Results, Misses Estimates By $0.10 EPS
InflaRx Posts Quarterly Earnings Results, Misses Estimates By $0.10 EPS
Western Asset Premier Bond Fund  Declares Monthly Dividend of $0.07
Western Asset Premier Bond Fund Declares Monthly Dividend of $0.07
Crown Castle International Corp. Declares Quarterly Dividend of $1.05
Crown Castle International Corp. Declares Quarterly Dividend of $1.05


Leave a Reply

© 2006-2018 Ticker Report. Google+.